ReviewExpert opinion on drug metabolism & toxicology2012
Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems.
Review in Expert opinion on drug metabolism & toxicology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed.
- Pathway-specific mechanisms, therapeutic applications, and toxicodynamic profile of acriflavine in cancer: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Biomimetic Protein Materials for Adjuvant-Free Dermal Penetration.ACS materials letters · 2026Article
- Nanotherapeutic potential in glaucoma associated ocular cancers.Discover oncology · 2026Review
- Engineering combination nanomedicines to overcome cancer resistance.RSC advances · 2026Review
- ROS-scavenging nanomaterials as emerging tools for bone tissue regeneration: A comprehensive review of recent progress.Acta pharmaceutica Sinica. B · 2025Review
- Eco-friendly synthesis and biomedical potential of silver nanoparticles using Pandanus dubius extract.Scientific reports · 2025Article
- Overcoming Oral Cavity Barriers for Peptide Delivery Using Advanced Pharmaceutical Techniques and Nano-Formulation Platforms.Biomedicines · 2025Review
- Advances in Oral Drug Delivery Systems for Natural Polyunsaturated Fatty Acids: Enhancing Bioavailability and Therapeutic Potential.Pharmaceutics · 2025Review
- The Road to Precision Nanomedicine: An Insight on Drug Repurposing and Advances in Nanoformulations for Treatment of Cancer.AAPS PharmSciTech · 2025Review
- Formulation and characterization of CMPI nanoparticles for enhanced targeting of brain nicotinic receptors by positive allosteric modulator.Scientific reports · 2025Article
- Nanomedicine and Its Role in Surgical Wound Infections: A Practical Approach.Bioengineering (Basel, Switzerland) · 2025Review
- Advancements and challenges in mRNA and ribonucleoprotein-based therapies: From delivery systems to clinical applications.Molecular therapy. Nucleic acids · 2024Review
- Novel gene therapy for drug-resistant melanoma: Synergistic combination of PTEN plasmid and BRD4 PROTAC-loaded lipid nanocarriers.Molecular therapy. Nucleic acids · 2024Article
- Intra-articular injection of stigmasterol-loaded nanoparticles reduce pain and inhibit the inflammation and joint destruction in osteoarthritis rat model: A pilot study.Drug delivery and translational research · 2024Article
- Article
- Extracellular vesicles derived from mesenchymal stem cells: the wine in Hebe's hands to treat skin aging.Precision clinical medicine · 2024Review
- Recent Developments in Nanoparticle Formulations for Resveratrol Encapsulation as an Anticancer Agent.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Challenges and Prospective of Enhancing Hydatid Cyst Chemotherapy by Nanotechnology and the Future of Nanobiosensors for Diagnosis.Tropical medicine and infectious disease · 2023Review
- Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems.Pharmaceutics · 2023Review
- An optimized live bacterial delivery vehicle safely and efficaciously delivers bacterially transcribed therapeutic nucleic acids.Engineering in life sciences · 2023Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionThe biggest challenge faced by the scientific community involved in drug development is to deliver safe and effective dosage of drugs without causing systemic toxicity. Therefore, novel nano-based delivery vehicles specifically targeting tumors but not normal tissues are urgently needed. AREAS COVERED: Nanoparticles have beneficial aspects but can be toxic themselves, which is always a concern for any drug or delivery agent. This review examines and details the toxicological aspects that should be considered when planning to use nanoparticles in animals or in man for drug delivery or imaging. Subjects discussed in this review include i) overviews of applications of various nanoparticles for drug delivery and imaging; ii) toxicological aspects to consider when selecting particular nanoparticles for use in various applications in animals or man; iii) hurdles faced when examining nanoparticle toxicity; and iv) current approaches for assessing nanoparticle toxicity. EXPERT OPINION: Nanotechnology has significant potential for advancing therapeutic efficacy and imaging in cancer; however, these agents can be toxic. Therefore, toxicity needs to be considered when selecting nanoparticles for a particular application. Methods for assessing nanoparticle toxicity need to be improved and standardized across all nanotechnology platforms in order to speed up the application of nanoparticle use in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.